In-house roundup: Antibody possession test uncertainty; fintech patent investment divide; SPCs for other industries
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

In-house roundup: Antibody possession test uncertainty; fintech patent investment divide; SPCs for other industries

Drugs

Managing IP rounds up the latest news and analysis from patent-focused businesses on fintech innovation, Section 112 and whether SPCs should be extended to agriculture and medical devices

Drugs

SCOTUS antibody case refusal raises Section 112 uncertainty

The US Supreme Court’s refusal to hear Amgen v Sanofi has renewed doubts over the value of antibody patents. Pharma firms such as Novartis and Bristol-Myers Squibb say they are exploring new ways to protect their innovations. Read More...

Agriculture companies disagree on need for SPCs

With high R&D costs and long development timelines, some agricultural firms argue that SPCs would bolster innovation in their field. Others say these extensions don’t fit with market dynamics and are not needed. Read more...

Innovation raises fintech patent investment challenges for traditional firms

Financial services businesses reveal the challenges behind how they allocate their patent budgets and choose between bread-and-butter legacy tech and revolutionary solutions they could monetise to generate high returns. Read more... 

Should medical device companies get SPCs?

Medical device firms in the US can apply for patent term extensions if they require regulatory approval before going to market, and some in-house counsel argue that the same rules should apply to European SPCs. Read more...

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.




more from across site and ros bottom lb

More from across our site

Darren Jiron, Finnegan’s managing partner in London, discusses the firm’s growth plans and misconceptions about US firm culture
The EMEA region research cycle has commenced - do not miss this opportunity to nominate your work from 2023!
A former partner at Stroock & Stroock & Lavan, which voted to dissolve in October, has joined McCarter & English
As ChatGPT celebrates its first birthday, we are still grappling with a multitude of IP concerns
Sources say an official role at an IP industry body is great for generating business leads, but that shouldn’t be the only motivation behind taking on the responsibility
Breton is commissioner for the internal market in the EU at the European Commission
Kupecz is a judge at the UPC Central Division in Germany
Hakki is senior partner at Shearman & Sterling in the US and Dejonghe is senior partner at Allen & Overy in London
Jaramillo is health minister for the Colombian government
Birss is a judge at the England and Wales Court of Appeal in London